Day One Biopharmaceuticals (DAWN) Equity Average (2022 - 2025)
Historic Equity Average for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $455.9 million.
- Day One Biopharmaceuticals' Equity Average rose 574.21% to $455.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.9 million, marking a year-over-year increase of 574.21%. This contributed to the annual value of $424.6 million for FY2024, which is 2515.73% up from last year.
- Day One Biopharmaceuticals' Equity Average amounted to $455.9 million in Q3 2025, which was up 574.21% from $470.2 million recorded in Q2 2025.
- In the past 5 years, Day One Biopharmaceuticals' Equity Average registered a high of $529.1 million during Q4 2024, and its lowest value of $301.8 million during Q2 2024.
- Over the past 4 years, Day One Biopharmaceuticals' median Equity Average value was $372.5 million (recorded in 2022), while the average stood at $393.3 million.
- Per our database at Business Quant, Day One Biopharmaceuticals' Equity Average crashed by 1692.19% in 2024 and then soared by 5580.59% in 2025.
- Quarter analysis of 4 years shows Day One Biopharmaceuticals' Equity Average stood at $347.6 million in 2022, then increased by 5.91% to $368.1 million in 2023, then skyrocketed by 43.75% to $529.1 million in 2024, then dropped by 13.85% to $455.9 million in 2025.
- Its last three reported values are $455.9 million in Q3 2025, $470.2 million for Q2 2025, and $491.1 million during Q1 2025.